NCT05975749View on ClinicalTrials.gov

Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2029

Conditions
Gastric Cancer
Interventions
DRUG

Serplulimab

Serplulimab: 4.5mg/Kg on day 1

DRUG

Trastuzuma

Trastuzuma: 8mg/Kg ( the first cycle)，6mg/Kg (the rest of cycles) on day 1

DRUG

Chemotherapy

Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease

Trial Locations (1)

2000000

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER